Despite Cancellation of Moderna’s mRNA Bird Flu Jab, Efforts for mRNA-LNP H5N1 Jab for Cattle Forges Ahead
Updated
Citing a decision based on safety, integrity, and trust connected to a product that “was not scientifically or ethically justifiable,” the US Department of Health and Human Services (HHS) notified Moderna on May 28 that it was terminating the company’s $776 million contract for the development of a bird flu vaccine for humans. That decision is undoubtedly the correct decision. Yet, meanwhile, realizing the danger to humans of the under-tested mRNA technology platform, the US government continues to fund research on H5 influenza mRNA-lipid nanoparticle (LNP) vaccines for use in cattle.
And to make matters worse—and essentially negate the progress made with the termination of HHS’s contract with Moderna—the US Food and Drug Administration (FDA) approved on May 31 a new Moderna COVID-19 mRNA jab called mNEXSPIKE®, which the DARPA partner noted was “for use in all adults 65 and older, as well as individuals 12 through 64 years of age with at least one underlying condition that put them at high risk for severe outcomes from COVID-19.”
While this article ponders the ongoing experimentation with mRNA technology in cattle for bird flu, the FDA’s approval of mNEXSPIKE® is reckless. Meanwhile, as we discuss cattle, the National Institutes of Health (NIH), the US Department of Agriculture (USDA), and the US Department of Energy continue to use federal funding to create mRNA-LNP jabs targeting highly pathogenic avian influenza (HPAI) H5N1 clade 2.3.4.4b in Holstein calves. The USDA allocated $824 million in emergency funding in May 2024 to bolster H5N1 efforts, including vaccine development for livestock, with ongoing research to evaluate effectiveness in lactating dairy cattle and eventually other animal species.
To help push the needle forward quickly, a 2025 preprint conducted by researchers at the USDA’s National Animal Disease Center and the University of Pennsylvania—who have received consulting fees from Big Pharma groups, including Pfizer—aims to paint the research in a glowing light, noting that an H5 mRNA-LNP vaccine induced robust antibody and T-cell responses in calves, offering partial protection against H5N1. However, notably, the preprint failed to report biodistribution data, only mentioning intramuscular administration but not whether the mRNA or LNPs were tracked in tissues beyond the intramuscular injection site. But make no mistake. We know that both the mRNA and toxic LNPs can also enter the bloodstream, leading to systemic distribution to organs across the body, including the liver, spleen, heart, and other tissues.
Concerningly, we also know mRNA-LNPs cross the blood-brain barrier, settling into essentially every organ in the human body, causing damage to the brain, heart, liver, and bone marrow in humans. Why isn’t this deadly hazard being studied in cattle? Thus far, no studies have directly quantified H5 mRNA-LNP biodistribution in cattle, particularly in lactating dairy cows, where H5N1 replication in the mammary glands raises significant concerns about milk safety.
The USDA-funded study notes that it plans to evaluate the vaccine in lactating cows in the future. Clearly, this analysis should incorporate biodistribution studies to determine whether the experimental jabs have a similar devastating effect on cattle as they did on humans. Will there be mRNA-LNP residues in the milk and meat products offered to consumers? This is an important question, especially given that the bovine vaccine is adapted from the same platform used in the deadly human COVID-19 mRNA jabs. The preprint study states:
“Highly pathogenic avian influenza (HPAI) H5 viruses threaten wild birds, poultry, and represent a human pandemic risk. In March 2024, an outbreak of HPAI clade 2.3.4.4b H5N1 virus was reported for the first time in dairy cattle. Since then, over 950 HPAI H5N1 (2.3.4.4b) cases in livestock herds of dairy cattle have been confirmed, and the virus has spread to 16 states in the US.
[A] severe case of HPAI H5 clade 2.3.4.4b resulted in the first US H5N1-related human death. Furthermore, there is an increased concern about mammalian adaptation of the HPAI H5 clade 2.3.4.4b and the risk of human-to-human transmission.”
An April 17, 2025, article in Cell Biomaterials joined Big Pharma and the government agencies to which it is closely aligned in magnifying the urgency of LNP vaccines to combat H5N1 HPAI clade 2.3.4.4b in livestock. Funded by inventors of patents related to the technology at play, POP Biotechnologies (which receives funding from Bill Gates), the article notes that the widespread outbreak of HPAI clade 2.3.4.4b H5N1 in North America has significantly impacted agriculture and poses a pandemic risk through human transmission. We must understand that there will be ongoing threats of future pandemics from these charlatans.
Like a replay from the horrors of the lethal experimental mRNA COVID-19 shots, the study emphasizes the looming risk to animals, insisting, “Vaccine preparedness is therefore critical.” The study authors note that their research demonstrates that recombinant H5 and N1 viral surface proteins can be displayed on immunogenic liposomes. They add that when used as a vaccine in mice, this formulation induced functional antibodies against H5 and N1, providing protection against lethal H5N1 challenge in both monovalent and bivalent forms. They state this streamlined nanoparticle-based H5 and N1 vaccine offers a promising approach for combating H5N1 HPAI clade 2.3.4.4b.
Government agencies supporting mRNA-LNP H5N1 research for cattle and other animals that will, in some manner, be ingested by humans must adopt the same stance as the HHS regarding the safety of mRNA and LNP products. Though hard to connect the same sentiment with the FDA’s sudden approval of mNEXSPIKE®, when explaining why HHS terminated Moderna’s contract, Andrew Nixon, HHS Communications Director, said what many of us have longed to hear, stating:
“After a rigorous review, we concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable. This is not simply about efficacy—it’s about safety, integrity, and trust. The reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public.”
For now, the writing is certainly on the wall, and the laser focus on mRNA-LNP jabs for cattle and other animals will undoubtedly move swiftly forward as long as support and funding is available. Did the HHS’s cancellation of Moderna’s $766 million contract for human H5N1 mRNA-LNP bird flu vaccines prompt a laser-focused movement to ensure a vaccine for cattle and other livestock comes to fruition quickly? For the few short days between HHS’s termination of Moderna’s contract and the FDA’s approval of mNEXSPIKE®, the Moderna decision represented a much-needed policy shift away from mRNA technology for human vaccines. Either way, for now, cattle-focused mRNA-LNP efforts remain undisturbed, with no evidence of redirected funds. And, unfortunately, there appears to be little to no concern about where the toxic mRNA and LNPs are distributed inside the animal’s body.
